Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 427

Similar articles for PubMed (Select 23845574)

1.

A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, Matsui T, Matsuo S, Travin MI, Jacobson AF.

JACC Cardiovasc Imaging. 2013 Jul;6(7):772-84. doi: 10.1016/j.jcmg.2013.02.007.

2.

Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.

Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD.

JACC Cardiovasc Imaging. 2012 Nov;5(11):1139-46. doi: 10.1016/j.jcmg.2012.02.019.

3.

Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J; ADMIRE-HF Investigators.

J Am Coll Cardiol. 2010 May 18;55(20):2212-21. doi: 10.1016/j.jacc.2010.01.014. Epub 2010 Feb 25.

4.

Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure.

Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, Tsuchihashi K, Shimamoto K.

J Nucl Med. 2004 Feb;45(2):155-63.

5.

Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death.

Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, Shimamoto K.

J Nucl Med. 2001 Dec;42(12):1757-67.

6.

Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts.

Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, Tsuchihashi K, Shimamoto K.

J Nucl Cardiol. 1998 Nov-Dec;5(6):579-90.

PMID:
9869480
7.

Myocardial sympathetic innervation and long-term left ventricular mechanical unloading.

Drakos SG, Athanasoulis T, Malliaras KG, Terrovitis JV, Diakos N, Koudoumas D, Ntalianis AS, Theodoropoulos SP, Yacoub MH, Nanas JN.

JACC Cardiovasc Imaging. 2010 Jan;3(1):64-70. doi: 10.1016/j.jcmg.2009.10.008. Epub 2010 Jan 12.

8.

A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.

Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, Matsui T, Matsuo S, Travin MI, Jacobson AF.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1673-82. doi: 10.1007/s00259-014-2759-x. Epub 2014 Mar 25.

9.

Cardiac mortality assessment improved by evaluation of cardiac sympathetic nerve activity in combination with hemoglobin and kidney function in chronic heart failure patients.

Doi T, Nakata T, Hashimoto A, Yuda S, Wakabayashi T, Kouzu H, Kaneko N, Hase M, Tsuchihashi K, Miura T.

J Nucl Med. 2012 May;53(5):731-40. doi: 10.2967/jnumed.111.095786. Epub 2012 Apr 10.

10.

Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.

Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, Shimoshige S, Uno K, Tsuchihashi K, Shimamoto K.

J Nucl Med. 2008 Feb;49(2):225-33. doi: 10.2967/jnumed.107.042564. Epub 2008 Jan 16.

11.

Short cardiac iodine-123-metaiodobenzylguanidine imaging protocol in heart failure.

Arimoto T, Sukekawa H, Harada M, Takayama S, Ikeno E, Nisugi K, Takeishi Y, Kubota I.

Circ J. 2008 Jul;72(7):1106-11.

12.
13.

Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study.

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, Asai M, Makino N, Kioka H, Kusuoka H, Hori M, Hoki N.

J Am Coll Cardiol. 2003 Jan 15;41(2):231-8.

PMID:
12535815
14.

Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, Loisance D, Castaigne A, Syrota A.

J Nucl Med. 1999 Jun;40(6):917-23.

15.
16.

Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.

Coutinho MC, Cortez-Dias N, Cantinho G, Conceição I, Oliveira A, Bordalo e Sá A, Gonçalves S, Almeida AG, de Carvalho M, Diogo AN.

Circ Cardiovasc Imaging. 2013 Sep;6(5):627-36. doi: 10.1161/CIRCIMAGING.112.000367. Epub 2013 Jul 5.

17.

I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study.

Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, Unlu M, Estorch M, Banerjee G, Jacobson AF.

Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):535-46. Epub 2007 Nov 28.

PMID:
18043919
18.

Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure.

Arimoto T, Takeishi Y, Niizeki T, Nozaki N, Hirono O, Watanabe T, Nitobe J, Tsunoda Y, Suzuki S, Koyama Y, Kitahara T, Okada A, Takahashi K, Kubota I.

J Card Fail. 2007 Feb;13(1):34-41.

PMID:
17339001
19.

[Assessment of most appropriate background subtraction method for quantification of 123I-metaiodobenzylguanidine (MIBG) myocardial uptake by comparing with plasma ANP and BNP].

Yahara Y, Nomura Y, Okamoto S, Saitou K, Okamoto R, Makino K, Aoki S, Takeda K.

Kaku Igaku. 2000 May;37(3):217-25. Japanese.

PMID:
10860352
20.

Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.

Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K.

Eur J Nucl Med Mol Imaging. 2005 Feb;32(2):186-94. Epub 2004 Sep 25.

PMID:
15452671
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk